secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001818331-24-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx prelim Q4 revenue >$57M, exome/genome rev +63% YoY; cash burn -51% YoY
-----------------------------------------------------------------------------

- Q4 continuing ops revenue >$57M (+24% YoY); exome/genome revenue >$38M (+63% YoY).
- Exome/genome test results 15,663 in Q4 (+99% YoY), now 27% of total test volume.
- Cash and equivalents $131M as of Dec 31, 2023.
- Q4 cash burn $33M, down 51% YoY and 21% sequentially; reiterates 2025 profitability path.
- Full year 2023 continuing ops revenue expected at least $193M; exceeded revised guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833124000003/0001818331-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833124000003/wgs-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001818331-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer